Pathology Asia Holdings

What Pathology Asia Holdings does

Pathology Asia Holdings is a Singapore-headquartered, private medical diagnostics platform founded in 2018 under TPG Capital sponsorship. The group operates a multi-brand laboratory network across six Asia-Pacific markets — Singapore, Malaysia, Vietnam, the Philippines, Indonesia, and Australia — collectively serving an addressable population of approximately 680 million. Operating brands include Innoquest Diagnostics (Singapore), Innoquest Pathology (Malaysia), Innoquest Indonesia, Singapore Diagnostics (Philippines), TissuPath (Australia), Safework Health (Australia), LifeStrands Genomics, DNA Lab, and the BioMark digital ecosystem.

Operational scale is substantial: the Singapore business processes more than 10,000 patient episodes daily; Malaysia alone has 1,200+ staff and 60 electronically-linked pathology facilities; the Philippines business serves 600+ hospital and clinic clients and roughly 100,000 patients per month. The group holds CAP and ISO 15189 accreditations, indicating compliance with international laboratory quality standards across regulated diagnostics.

The business model is transaction fee-based laboratory diagnostic testing, with a sales-led, doctor-led go-to-market approach operating as a medically managed organization. Revenue is generated per test ordered by referring clinicians and healthcare institutions, spanning routine pathology, specialty diagnostics, genomics and molecular testing, and occupational health screening. The BioMark digital ecosystem serves as the connective layer across multi-country operations, supporting ordering, logistics, and results delivery.

Name

Pathology Asia Holdings

Legal name

Pathology Asia

Website

https://www.pathologyasia.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Pathology Asia Holdings is a Singapore-headquartered medical diagnostics platform operating multi-brand laboratory networks across six Asia-Pacific countries (Singapore, Malaysia, Vietnam, Philippines, Indonesia, Australia). The group provides transaction-fee-based pathology, genomics, and occupational health testing to hospitals, clinics, and referring clinicians serving 680 million people.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

akta.pro secondary industries

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)

Keywords

• Clinical diagnostic services
• Medical laboratory testing
• Pathology services
• In-vitro diagnostics
• Genetic testing services

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Diagnostic Testing Services: Pathology Asia operates clinical diagnostic laboratories across Southeast Asia and Australia, providing a comprehensive range of in-vitro diagnostic tests to healthcare providers. Revenue is generated through test fees billed per episode, with services delivered via an extensive network of satellite laboratories and courier operations. The company processes over 10,000 patient episodes daily across its Singapore operations alone.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Pathology Asia operates full-service clinical diagnostic laboratories providing comprehensive in-vitro diagnostic (IVD) testing across allergy, biochemistry, bacteriology, cytopathology, haematology, histopathology, immunology, microbiology, molecular biology, serology, special chemistry and toxicology disciplines. It complements testing with on-site corporate health screening, phlebotomy services, an extensive courier network, and a digital BioMark ecosystem that connects laboratories with clinicians, patients and third-party stakeholders across Southeast Asia and Australia.

Product overview

Pathology Asia Holdings is a diversified diagnostic services provider operating a platform-plus-multiple-brands architecture across three main divisions: Clinical Diagnostics (Innoquest Diagnostics in Singapore, Innoquest Pathology in Malaysia, Innoquest Indonesia, Safework Health in Australia, Singapore Diagnostics in the Philippines, and TissuPath in Australia), Genomics and Life Sciences (LifeStrands and DNA Lab for genetic testing and molecular diagnostics), and Digital Health (BioMark digital ecosystem and e-Results Portal). The company offers comprehensive laboratory testing services including allergy, biochemistry, bacteriology, cytopathology, haematology, histopathology, immunology, microbiology, molecular biology, serology, and special chemistry, along with supporting services such as on-site screening, phlebotomy, and courier services.

Differentiator

Problem solved

Functional benefit

Brands

• Innoquest Diagnostics: Clinical diagnostic services in Singapore, formerly a merger of Innovative Diagnostics and Quest Laboratories
• Innoquest Pathology
• Innoquest Indonesia
• Safework Health
• Singapore Diagnostics (SGD)
• TissuPath
• LifeStrands Genomics
• DNA Lab
• BioMark

Products and services

• Innoquest Diagnostics Full-service clinical diagnostic laboratory service in Singapore, formed from the merger of Innovative Diagnostics and Quest Laboratories, operating from eight facilities with capacity to perform tests for over 10,000 patient episodes a day. Offers a comprehensive IVD test menu including allergy, biochemistry, haematology, microbiology, molecular biology, histopathology, serology and special chemistry, with CAP and ISO 15189 accreditations.
• Innoquest Pathology Malaysia's largest private provider of diagnostic laboratory services (formerly Gribbles Pathology), with over 1,200 staff and a network of 60 electronically-linked pathology facilities throughout Peninsular Malaysia, Sabah and Sarawak. Dual CAP and ISO 15189 accredited across disciplines including haematology, clinical chemistry, drug & toxicology, molecular, bacteriology, serology and anatomical pathology.
• Innoquest Indonesia Clinical diagnostic laboratory service in Indonesia, operating from a Core Lab in Jakarta equipped with a total laboratory system capable of handling 10,000 samples daily.
• Safework Health National Australian provider of workplace health and safety products and services, including drug and alcohol testing, laboratory testing, pre-employment medicals, drug and alcohol training courses, and workplace environmental testing, with NATA accredited laboratories.
• Singapore Diagnostics (SGD) One of the largest laboratories in the Philippines, processing laboratory tests for over 600 hospitals, clinic labs and healthcare institutions and serving up to 100,000 patients every month. CAP accredited.
• TissuPath Melbourne's premier specialist anatomical pathology laboratory, specialising in surgical pathology.
• LifeStrands Genomics Clinical genetics testing and genomics services division providing PreNatal DNA testing, IVF/reproductive health genetic tests and cancer testing, with operations in Singapore and Australia. The largest reproductive genetics player in Malaysia following the acquisition of DNA Lab.
• DNA Lab Leading provider of genetic screening and molecular diagnostic services in Malaysia with over 15 years of experience and pioneer for non-invasive prenatal testing (NIPT) in Malaysia since 2013. Offers prenatal and women's health, oncology, and clinical genomics services.
• BioMark Digitally-connected ecosystem that connects laboratories with healthcare providers, patients and third-party stakeholders on a single seamless platform, enabling increased adherence to treatments and cost savings. Acquired by Pathology Asia in 2020.
• e-Results Portal (iQ) Online portal for clinicians to access patient laboratory results electronically, part of the BioMark digital ecosystem connecting laboratories with clinicians and patients.
• On-Site Health Screening On-site health screening projects delivered to corporate clients and specialist centres, supported by an experienced project management team and highly-skilled phlebotomists with personalised service across lab and on-site operations.
• Phlebotomy Services Sample collection services provided by trained phlebotomists, including on-site sample collection for corporate clients and through Pathology Asia's laboratory network across Southeast Asia and Australia.
• Courier and Logistics Services Dedicated in-house courier and dispatch rider network handling daily specimen pickup from clinicians and delivery of laboratory reports across Malaysia, Singapore and other operating countries, plus consumables restocking for clients.
• Lab Consumables Supply Supply of laboratory consumables to doctors and clients via the my.biomarking.com online portal, with supplies usually delivered within one to two business days.

Quantifiable outcome

• Over 10,000 patient episodes daily capacity in Singapore operations
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Global Diagnostics Network (GDN)coreStrategic or Co-development Partner · 10 January 2024Pathology Asia joined the Global Diagnostics Network (GDN) in January 2024 (introduced July 2023), a strategic working group of diagnostic laboratories from around the world committed to introducing local innovations to generate enhanced diagnostics insights and improve global healthcare. GDN was conceptualized by US-based Quest Diagnostics and has presence in countries with two-thirds of the world's population and over 90% of the global pharmaceutical market.
• Hanh Phuc Women & Children's Hospital (Vietnam)minorStrategic or Co-development PartnerQuest Laboratories Vietnam established a laboratory at Hanh Phuc Women & Children's Hospital in Ho Chi Minh City in 2011, marking Quest's entry into Vietnam.

Scale indicators7 records

Recent moves12 records

Expansion highlights5 records

Broad incumbents

• SGS: Global testing, inspection and certification company with clinical and life sciences lab services. Adjacent comparable on lab operations, accreditation depth and multi-country execution.
• Laboratory Corporation of America (Labcorp): Global clinical laboratory network offering routine, esoteric and clinical trial testing. Comparable in scale and test menu breadth; also a GDN member and a competitor for clinical trial central lab work.
• Quest Diagnostics: US-based reference laboratory and convenor of the Global Diagnostics Network that Pathology Asia joined in 2024. A direct capability comparable and GDN partner; a key competitor for cross-border reference work.
• Sonic Healthcare: Global medical diagnostics leader with operations across Australia, Europe and the US. A broader incumbent offering similar pathology services; competes directly with Pathology Asia's Australian footprint and serves as a comparable scale benchmark.
• Eurofins Scientific: Global leader in bioanalytical and clinical testing services. Broad incumbent in clinical diagnostics with comparable cross-geography footprint and clinical trial lab services.

Direct peers

• 4Cyte Pathology: Australian specialist pathology network with bulk-billed model and broad clinician base. Pathology Asia's CTO previously worked at 4Cyte, and the network competes with TissuPath across Australian clinicians.
• Dr. Lal PathLabs: India's largest diagnostic services chain offering routine and specialty lab testing through a hub-and-spoke model. Directly comparable as Pathology Asia's new Group CEO previously led Dr. Lal PathLabs and the regional roll-up playbook is similar.
• Healius: Australian operator of pathology, imaging and day hospitals with extensive lab network. Pathology Asia's CTO came from Healius, and Healius's Australian diagnostics business directly overlaps with TissuPath and LifeStrands Australia.

Regional players

• IHH Healthcare: Asia's largest private hospital group operating in Malaysia, Singapore, Turkey and India. Anchors in-house diagnostics demand that competes with Pathology Asia's hospital lab services in overlapping geographies.
• Bangkok Lab (Bangkok Dusit Medical Services): Thailand-based diagnostics arm of the Bangkok Hospital network. Regional peer with hospital-anchored lab model competing for SE Asian corporate and clinician accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pathology-asia

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries17 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathology Asia Holdings